Search

Displaying results 7111 - 7120 of 10000 in total
  1. Drug

    Cimlanod

    go.drugbank.com/drugs/DB14983
    Investigational

    Cimlanod is under investigation in clinical trial NCT02819271 (A First-in-Human Study of the Safety of Single Continuous Intravenous (IV) Infusions of CXL-1427 for up to 48 Hours in Healthy Volunteers)

  2. Drug

    Alcestobart

    go.drugbank.com/drugs/DB28487
    Investigational

    Alcestobart is under investigation in clinical trial NCT05909904 (A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma).

  3. Drug

    Refanezumab

    go.drugbank.com/drugs/DB14908
    Investigational

    Refanezumab is under investigation in clinical trial NCT00833989 (Safety Escalating Repeat IV, in Stroke Patients).

  4. Drug

    Nerinetide

    go.drugbank.com/drugs/DB12595
    Investigational

    Na 1 is under investigation in clinical trial NCT00728182 (Evaluating Neuroprotection in Aneurysm Coiling Therapy).

  5. Drug

    Bifikafusp alfa

    go.drugbank.com/drugs/DB19185
    Investigational

    Bifikafusp alfa is under investigation in clinical trial NCT05329792 (L19IL2/L19TNF in Skin Cancer Patients).

    Synonyms: Immunoglobulin, anti-(human fibronectin ed-b domain) (synthetic human clone l19 scfv fragment) fusion protein with human interleukin 2
  6. Drug

    Martinostat

    go.drugbank.com/drugs/DB14979
    Investigational

    Martinostat is under investigation in clinical trial NCT03721211 (Imaging With [11C]Martinostat in Breast Cancer).

  7. Drug

    Fibronectin

    go.drugbank.com/drugs/DB15150
    Investigational

    Fibronectin is under investigation in clinical trial NCT01812239 (Vaginal Progesterone in Twins With Short Cervix).

  8. Drug

    AG0301-COVID19

    go.drugbank.com/drugs/DB15856
    Investigational

    The candidate is a plasmid DNA vaccine developed using an intradermal gene transfer method targeting the SARS-CoV-2 spike protein. … On September 8, 2020 AnGes announced collaboration with Brickell Biotech, Inc. following completion of Phase 1/2 clinical studies (NCT04463472).

  9. Drug

    Streptococcus pneumoniae type 8 capsular polysaccharide diphtheria CRM197 protein conjugate antigen

    go.drugbank.com/drugs/DB16713
    ApprovedInvestigational

    The saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate.

  10. Drug

    Streptococcus pneumoniae type 11A capsular polysaccharide diphtheria CRM197 protein conjugate antigen

    go.drugbank.com/drugs/DB16715
    ApprovedInvestigational

    The saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate.